A new collaboration among UPMC Hillman Cancer Center, the University of Pittsburgh and New Jersey-based biotechnology company Avalon GloboCare Corp. (NASDAQ: AVCO) aims to develop new cancerA new collaboration among
Previously Announced Execution of Definitive Agreement to Acquire SenlangBio
SenlangBio Generated Revenue of USD $1.2 Million for the Three Months Ended March 31, 2021 and Projects $5
Avalon GloboCare Corp (NASDAQ:AVCO) has agreed to acquire Hebei Senlang Biotechnology, dubbed SenlangBio, a China-based cell therapy company, in an all-stock…
Avalon GloboCare Corp. (NASDAQ:AVCO) ("Avalon" or "the Company"), a clinical-stage global developer of cell-based technologies and therapeutics, today announced that it has entered into a